Micropos Medical (MPOS) Q3 2025 earnings summary

Executive summary

• Net sales for Jan–Sep 2025 reached 6,723 TSEK, up from 2,084 TSEK year-over-year.

• Result after financial items improved to -15,630 TSEK from -17,291 TSEK year-over-year.

• Strong market interest in Augmented SBRT (ASBRT) and Raypilot System, with new installations and collaborations in Europe and the US.

• Strategic focus on expanding customer base to larger clinics and early adopters.

Financial highlights

• Q3 net sales were 743 TSEK, up from 72 TSEK in Q3 2024.

• Net loss per share improved to -0.09 SEK from -0.11 SEK year-over-year.

• Equity at period end was 19,823 TSEK, up from 14,700 TSEK.

• Cash flow for the period was 8,570 TSEK, with cash and equivalents at 16,560 TSEK.

• Solid equity ratio of 82% compared to 72% last year.

Outlook and guidance

• Future prospects are positive, with expectations that SBRT will become standard treatment, increasing demand for motion monitoring.

• Company anticipates need for additional capital in H1 2026 due to slow ramp-up of patient volumes.